NASDAQ · Financial Statements

Bone Biologics Corp (BBLG) Revenue, Earnings & Financial Statements

$0.31 NASDAQ: BBLG Market Cap $1.05M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Bone Biologics Corp most recently reported annual revenue of $0, a net loss of $3.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Bone Biologics Corp: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of $3.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$0$0$0$0$0$0$0$0$0$0
Operating Expenses$20.0M$3.0M$3.0M$2.0M$1.0M$1.0M$4.0M$9.0M$4.0M$3.0M
Operating Profit−$20.0M−$3.0M−$3.0M−$2.0M−$1.0M−$1.0M−$4.0M−$9.0M−$4.0M−$3.0M
Other Income−$1.0M−$4.0M−$2.0M−$1.0M−$1.0M−$1.0M$2.0M$0$0$0
Interest$3.0M$4.0M$1.0M$1.0M$1.0M$1.0M$1.0M$0$0$0
Depreciation$0$0$0$0$0$0$0$9.0M$4.0M$0
Profit Before Tax−$21.0M−$7.0M−$4.0M−$3.0M−$2.0M−$2.0M−$1.0M−$9.0M−$4.0M−$3.0M
Tax rate (%)-0.0%-0.0%-0.0%-0.1%-0.1%0.0%0.0%0.0%0.0%0.0%
Net Profit−$26.0M−$7.0M−$4.0M−$3.0M−$2.0M−$2.0M−$1.0M−$9.0M−$4.0M−$3.0M
EPS−$24840.00−$6480.00−$3173.58−$66.97−$35.68−$37.35−$31.20−$34.01−$4.83−$2.65

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$1.0M$1.0M$1.0M$1.0M$2.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M
Operating Profit−$1.0M−$1.0M−$1.0M−$1.0M−$2.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$2.0M−$1.0M−$1.0M−$1.0M−$2.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$2.0M−$1.0M−$1.0M−$1.0M−$2.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M−$1.0M
EPS−$3.38−$1.31−$0.67−$2.37−$0.48−$0.32−$1.33−$0.37−$0.63−$0.43−$0.43−$0.17

Over the 10 years reported for Bone Biologics Corp, borrowings decreased from $9.0M in 2016 to $0 in 2025, cash stood at $5.0M in the latest year, shareholders' equity was $0.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$1.0M$1.0M$1.0M$0$0$7.0M$8.0M$4.0M$4.0M$6.0M
Current Assets$1.0M$1.0M$1.0M$0$0$7.0M$8.0M$4.0M$4.0M$6.0M
Cash$1.0M$1.0M$1.0M$0$0$7.0M$8.0M$3.0M$3.0M$5.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$1.0M$0$0$0
Fixed Assets$0$0$0$0$0$0$0$0$0$0
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$10.0M$9.0M$10.0M$12.0M$14.0M$0$3.0M$1.0M$0$0
Current Liabilities$2.0M$1.0M$10.0M$1.0M$14.0M$0$3.0M$1.0M$0$0
Borrowings$9.0M$8.0M$9.0M$11.0M$12.0M$0$0$0$0$0
Other Liabilities$1.0M$1.0M$1.0M$1.0M$2.0M$0$3.0M$1.0M$0$0
Equity$0$0$0$0$0$0$0$0$0$0
Reserves−$8.0M−$8.0M−$9.0M−$12.0M−$14.0M$7.0M$6.0M$3.0M$3.0M$5.0M

For Bone Biologics Corp, operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $3.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$7.0M−$3.0M−$4.0M−$3.0M$0−$1.0M−$4.0M−$10.0M−$4.0M−$3.0M
Investing Cash Flow$0$0$0$0$0$0$0$0$0$0
Financing Cash Flow$1.0M$0$0$0$0$0$0$0$5.0M$0
Net Cash Flow$0$0$0−$1.0M$0$7.0M$1.0M−$5.0M$0$2.0M
Free Cash Flow−$7.0M−$3.0M−$4.0M−$3.0M$0−$1.0M−$4.0M−$10.0M−$4.0M−$3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA1.70
FCF Yield-217.89%
Quick Ratio13.38
Interest Coverage—
Return 1Y-81.01%
Return 3Y-98.94%
Return 5Y-99.99%

Bone Biologics Corp (BBLG) financials — frequently asked questions

What is Bone Biologics Corp's annual revenue?

Bone Biologics Corp (BBLG) reported annual revenue of $0 in its most recent fiscal year.

What is Bone Biologics Corp's net profit?

Bone Biologics Corp (BBLG) reported a net loss of $3.0M in its most recent fiscal year.

What is BBLG EV/EBITDA?

Bone Biologics Corp's enterprise value to EBITDA (EV/EBITDA) ratio is 1.70.

Revenue and earnings of other Medical - Devices stocks

ABT revenue $44.3BISRG revenue $10.1BMDT revenue $36.4BSYK revenue $25.1BBSX revenue $20.1BEW revenue $6.1BRMD revenue $5.7BDXCM revenue $4.7BPHG revenue $17.8BZBH revenue $8.2BAll Medical - Devices stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
BBLG Overview BBLG Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.